Buys
Open market- Shares
- Avg price
- Total value
Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships at Schrodinger, Inc.
Issuer-level insider activity
- Role
- President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
- Issuer ticker
- SDGR on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Karen Akinsanya in Schrodinger, Inc.
Sells
Open market- Shares
- -3,572
- Avg price
- $12.34
- Total value
- -$44,080
Net
Past year- Shares
- -3,572
- Share %
- -100%
- Total value
- -$44,080
Reported holdings for Karen Akinsanya in Schrodinger, Inc.
Form 4 holding
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
Schrodinger, Inc.
- Security class
- Common Stock
- Shares / value
- 69,956
- Estimated value
- $902,642
- Report date
- 05 Mar 2026
- Price
- $12.90
- Ownership
- Direct
Form 4 holding
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
Schrodinger, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 48,500
- Estimated value
- Report date
- 02 Mar 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Karen Akinsanya in Schrodinger, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.